May Reyes, MD
Endocrinology, Diabetes & Metabolism · Albuquerque, NMNPI 1578624631
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 177 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$592
- Insulet Corporation$548
- Lilly USA, LLC$347
- Abbott$285
- Novo Nordisk$242
- Boehringer Ingelheim$201
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $592 |
| Insulet Corporation | 25 | $548 |
| Lilly USA, LLC | 19 | $347 |
| Abbott | 13 | $285 |
| Novo Nordisk | 11 | $242 |
| Boehringer Ingelheim | 12 | $201 |
| Medtronic(2 entities) | 7 | $138 |
| Xeris Pharmaceuticals, Inc. | 6 | $133 |
| Dexcom, Inc. | 7 | $133 |
| AstraZeneca | 6 | $95 |
| Tandem Diabetes Care, Inc. | 4 | $79 |
| Johnson & Johnson(2 entities) | 3 | $70 |
| Acella Pharmaceuticals, LLC | 4 | $68 |
| Radius Health, Inc. | 4 | $67 |
| Novartis | 3 | $59 |
| BETA Bionics, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Pfizer | 2 | $42 |
| Bristol Myers Squibb | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Bayer | 2 | $33 |
| Ascensia Diabetes Care US Inc. | 1 | $28 |
| AbbVie | 2 | $26 |
| BD | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| GSK | 1 | $14 |
How this compares
$3,455 in reported general payments places this provider in the 65th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 290 | $283,959 |
| TrulicityDulaglutide | 190 | $251,014 |
| FarxigaDapagliflozin Propanediol | 204 | $185,804 |
| MounjaroTirzepatide | 144 | $184,687 |
| JardianceEmpagliflozin | 64 | $72,840 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $58,912 |
| JanuviaSitagliptin Phosphate | 39 | $56,997 |
| Teriparatide | 16 | $52,508 |
| SynthroidLevothyroxine Sodium | 375 | $31,388 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 76 | $31,214 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $27,255 |
| Levothyroxine Sodium | 1,889 | $26,385 |
| Insulin Aspart FlexpenInsulin Aspart | 116 | $23,484 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $23,093 |
| Insulin Glargine-Yfgn | 165 | $22,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Baqsimi | $347 | $453,503384 claims |
| Novo NordiskOzempic, Novolog, Levemir | $242 | $296,595336 claims |
| AstraZenecaFarxiga | $95 | $185,804204 claims |
| Boehringer IngelheimJardiance | $201 | $72,84064 claims |
| AbbVieSynthroid | $26 | $31,388375 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $26,3851,889 claims |
| PfizerLevoxyl | $42 | $11,685259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Albuquerque
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- Jeremy GleesonAlbuquerque$46K
- David SchadeAlbuquerque$16K
- Mansi MehtaAlbuquerque$15K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Ivan PinonAlbuquerque$5K
- Namrata JannareddyAlbuquerque$4K
- Anita Sloan-GarciaAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.